Hyperbaric oxygen therapy — HBOT, in clinical shorthand — was the technology that built the dive medicine literature, then quietly rebuilt itself into a longevity modality over the last decade of peer-reviewed work coming out of Tel Aviv, Cleveland, and a small group of US academic centers. The mechanism is older than the marketing. The marketing has, in places, run ahead of the data. The job of a longevity facility is to know which is which.
What we tell members on the first walk-through is the cleanest version of the truth. At one and a half atmospheres, breathing nearly pure oxygen for an hour, the partial pressure of dissolved oxygen in plasma rises roughly fifteen-fold over what it is at sea level. The body becomes, briefly, a very different oxygen economy. Not because hemoglobin holds more — it is already nearly saturated at one ATA — but because the small fraction of oxygen that travels dissolved in plasma, normally a rounding error, becomes a substantial delivery vehicle to tissues that hemoglobin reaches poorly. Capillaries with damaged endothelium. Areas downstream of microvascular insufficiency. Tissues whose mitochondrial demand has out-paced their perfusion.
Hyperoxic-hypoxic paradox — the actual mechanism
For the first sixty years of the field, HBOT was understood as oxygen delivery. Modern work shifted the framing. The interesting biology happens in the transitions — the moments when oxygen is high, then briefly normal, then high again. That cycle, repeated across a session and across a course, looks at the cellular level a great deal like the signal an exercising muscle receives. The cell experiences relative hypoxia, which activates HIF-1α (hypoxia-inducible factor) and the angiogenic cascade downstream of it. New capillary growth, mobilization of stem cells from the bone marrow, and a measurable shift toward a regenerative phenotype. Shai Efrati and colleagues at Tel Aviv published the cleanest mechanistic frame for this in their 2020 series on telomere length and senescent-cell clearance, and the work has since been replicated in vascular cognitive impairment populations and post-COVID fatigue cohorts.
The takeaway, said cleanly: HBOT is not "more oxygen." It is a paradoxical hormetic stimulus that uses oxygen as the lever. The chamber is doing what altitude does, but in reverse, and on a schedule the clinician controls.
What is settled, what is plausible
What is settled is the FDA-approved indication list — decompression sickness, severe carbon monoxide poisoning, diabetic foot ulcers, certain radiation injuries, osteomyelitis, and a small number of others. None of those are why our members come.
What is settled but off-label is the cognitive-recovery work in stroke, traumatic brain injury, and post-concussion syndrome, where double-blind randomized trials in the last decade have produced effect sizes substantial enough that the major review boards now classify HBOT as supported evidence rather than speculation. The dosing in those studies is consistent: forty to sixty sessions, roughly an hour each, at 1.5 to 2.0 ATA, on most days of the week.
What is plausible but not yet settled is the longevity application. The Efrati group's work showing telomere lengthening and reductions in senescent T-cell fractions in healthy older adults was a small study with a serious design and an unusual result. It has not, as of this writing, been replicated at the same effect size by an independent lab. We treat it the way a careful clinician treats any single-site finding: with respect, with curiosity, and without making it the basis of a marketing claim.
What is over-marketed, in our experience, is everything in the consumer space that promises HBOT will reverse aging in twenty sessions, build athletic performance overnight, or rescue conditions for which the mechanistic story is thin. The signal is real. It is not big enough to support those claims.
What our members actually use it for
The protocol on our floor is built around three populations. The first is post-injury or post-surgical recovery — rotator-cuff repairs, ACL reconstructions, oral-surgery flaps, and a steady stream of soft-tissue issues that simply heal faster when capillary perfusion is supported through the early granulation window. This is the indication with the deepest mechanistic and clinical support and the one most members do not initially come in for.
The second is cognitive demand and post-concussion. Members in their forties and fifties whose work is intellectual, whose sleep is partial, and who have had at least one significant knock to the head somewhere in the past two decades. The protocol there is longer — thirty to sixty sessions across a quarter — and the outcomes we measure are reaction time, working memory, and subjective clarity. Members do not always notice the gain in real time; they notice that the slope of their cognitive year shifts upward in retrospect.
The third is the longevity-curious cohort, who enter without a specific complaint and use HBOT as a quarterly compounding stimulus. We are honest with them about what is settled and what is plausible. The dosing is two sessions per week for ten to twelve weeks, repeated annually. The biomarkers we follow are inflammatory, lipid-particle, and where appropriate, repeat measures of telomere length through commercial assays whose limits we explain in the consultation.
Side-effect math
The most common adverse event is barotrauma to the middle ear — a sensation of pressure that members who have ever flown will recognize. It is preventable in nearly every case by teaching the Valsalva or Toynbee maneuver during compression and is the reason new members spend a few minutes with our chamber operator before their first descent. Sinus barotrauma occurs in members congested at the time of session and is also preventable by simply rescheduling. Oxygen toxicity at our 1.5 ATA dosing window is rare and self-limiting; it is monitored for and addressed before it becomes an issue.
The contraindication list is short and nearly always managed at intake: untreated pneumothorax, certain chemotherapy agents in active treatment, severe COPD with retention physiology, severe claustrophobia (the chamber is windowed, but it is still a chamber), and pregnancy in the first trimester. These are not subtle and they are caught at the medical clearance performed by Dr. Chaudhari through Elite Aesthetic MD — his independent practice located inside WEF — before any member begins a course.
How we set it up
The chamber on our floor is a monoplace FDA-cleared unit, operated under a written WEF protocol, informed by Dr. Chaudhari at Elite Aesthetic MD (the independent practice located inside the building). Members lie supine for sixty minutes. The compression and decompression phases together account for roughly fifteen of those sixty minutes, leaving forty-five minutes at depth. We dose oxygen at 100 percent through a hood or mask depending on member tolerance. The room is quiet. The lighting is low. Members read or sleep; some, in our experience, do their best thinking of the week.
Sessions are scheduled in the late morning or mid-afternoon when possible — a small but consistent observation in the literature is that HBOT is best tolerated, and most clinically effective, when it is not stacked on a nervous system that is acutely sympathetic. The post-session protocol matters less than the pre-session one. Hydration ahead of time. A complete meal earlier in the day, not skipped. Sleep two nights prior, not one.
What it is not
HBOT is not a cure. It is not a replacement for sleep, training, or food. It is not a stand-alone longevity intervention; the clean studies all run it as an adjunct to a coherent program. It is not, on our floor, a service we sell separately to drop-ins; modality access is reserved for members because the mechanistic logic only works inside a programmed context that makes the rest of the inputs — sleep, training load, nutritional substrate, recovery — legible to the protocol.
What it is, in the right population, with the right dosing, and with honest expectations, is one of the more interesting pieces of physiology a member can rent for an hour at a time. The mechanism is well-described. The dose is well-defined. The downside is small and managed. The upside is plausible and, for the first two indications, well-supported. That is what a longevity facility is supposed to look like.
— Published in The Bioneer, Journal.